标题
Clinical trials of CAR-T cells in China
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-10-24
DOI
10.1186/s13045-017-0535-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving molecular diagnostic (MD) testing in U.S. routine clinical practice.
- (2017) Lisa I Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
- (2017) Frank (Xiaohu) Fan et al. JOURNAL OF CLINICAL ONCOLOGY
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
- (2017) Kai-chao Feng et al. Journal of Hematology & Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- CD70, a novel target of CAR T-cell therapy for gliomas
- (2017) Linchun Jin et al. NEURO-ONCOLOGY
- Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy
- (2017) Lisa Rosenbaum NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
- (2017) Jeremy S. Abramson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- T-cell receptor-engineered T cells for cancer treatment: current status and future directions
- (2017) Yu Ping et al. Protein & Cell
- CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
- (2016) Jae H. Park et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- Immune Checkpoint Therapy in Renal Cell Carcinoma
- (2016) Chung-Han Lee et al. CANCER JOURNAL
- ICOS Promotes the Function of CD4+Effector T Cells during Anti-OX40–Mediated Tumor Rejection
- (2016) Todd C. Metzger et al. CANCER RESEARCH
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
- (2016) M. Ruella et al. CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
- (2016) Raghvendra M. Srivastava et al. CLINICAL CANCER RESEARCH
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies
- (2016) CJ Turtle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
- (2016) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
- (2016) Yozo Nakazawa et al. Journal of Hematology & Oncology
- High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
- (2016) Lorenzo Falchi et al. Journal of Hematology & Oncology
- Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
- (2016) Bo Cai et al. Journal of Hematology & Oncology
- Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
- (2016) Yongxian Hu et al. Journal of Hematology & Oncology
- Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
- (2016) De-Gang Song et al. Journal of Hematology & Oncology
- Emerging therapeutic agents for lung cancer
- (2016) Bhagirathbhai Dholaria et al. Journal of Hematology & Oncology
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Dependent Coverage under the ACA and Medicaid Coverage for Childbirth
- (2016) Yaa Akosa Antwi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
- (2016) Fengtao You et al. Science China-Life Sciences
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- TCR-engineered T cells to treat tumors: Seeing but not touching?
- (2016) Reno Debets et al. SEMINARS IN IMMUNOLOGY
- Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape
- (2016) Cameron J. Turtle et al. Expert Review of Hematology
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
- (2016) Ju Yeon Lee et al. Nature Communications
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Are All Chimeric Antigen Receptors Created Equal?
- (2015) Jae H. Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
- (2015) Frédéric Baron et al. Journal of Hematology & Oncology
- Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society
- (2015) Frédéric Baron et al. Journal of Hematology & Oncology
- AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells
- (2015) Dongmei Fan et al. Journal of Hematology & Oncology
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
- (2015) David M. Barrett et al. JOURNAL OF IMMUNOLOGY
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
- (2015) Miguel F. Sanmamed et al. SEMINARS IN ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
- (2014) Loren Gragert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy for Cancer
- (2013) David M. Barrett et al. Annual Review of Medicine
- Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia
- (2013) David M. Barrett et al. HUMAN GENE THERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
- (2013) Lihua E. Budde et al. PLoS One
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
- (2013) Andre Kunert et al. Frontiers in Immunology
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy for B-cell Malignancies
- (2012) David L Porter et al. Journal of Cancer
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
- (2011) D.-G. Song et al. BLOOD
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus-Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after HLA-Mismatched Allogeneic Transplantation following Nonmyeloablative Conditioning
- (2010) Frédéric Baron et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
- (2010) Ted A. Gooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started